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Effective Knowledge Transfer during Biopharmaceutical Technology 
Transfer 




Martin J. Lipa, M.S., Pharmaceutical Regulatory Science Team, Technological University Dublin  
Paige Kane, Ph.D., Pharmaceutical Regulatory Science Team, Technological University Dublin  
Anne Greene, Ph.D., Professor, and lead of Pharmaceutical Regulatory Science Team, 
Technological University Dublin 
 
ABSTRACT 
Author’s Note: This is the author’s submitted manuscript which has subsequently been published 
in the Journal of Validation Technology (www.ivtnetwork.com, Volume 25, Issue 4 – August 2019). 
While knowledge management (KM) has been widely applied in other sectors, the international 
biopharmaceutical sector has struggled with the meaningful and sustained application of 
effective KM practices.  This is evident even though KM has been highlighted in regulatory 
guidance for over 10 years, and the positive business impact of KM is well recognized in other 
sectors.  This paper focuses on the topic of KM as applied to biopharmaceutical technology 
transfer, introducing new research that explores the importance and effectiveness of knowledge 
transfer as an integral component of a biopharmaceutical product technology transfer.  Results 
from multiple sources explored in this paper are well aligned in recognizing that knowledge 
transfer is very important to enable technology transfer, yet the biopharmaceutical sector is not 
very effective at this knowledge transfer.  This is especially true of tacit knowledge transfer which 
is often reported to be ineffective.  Additional research will further define the barriers to improve 
knowledge transfer effectiveness and how the biopharmaceutical sector might improve in this 




This paper presents a case for the need to improve knowledge transfer (more broadly knowledge 
management) as part the technology transfer stage in the pharmaceutical product lifecycle.  The 
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importance of effective knowledge transfer to enabling successful technology transfer is 
established and the current effectiveness is characterized using multiple inputs which are 
assessed, reported, and discussed.   
 
While knowledge management (KM) approaches have been widely applied in other sectors, the 
international biopharmaceutical sector has struggled with meaningful and sustained application 
of effective KM practices.  Furthermore, recent research carried out by the TU Dublin 
Pharmaceutical Regulatory Science Team [1] has identified that technology transfer occurs over 
many phases of the product lifecycle and that knowledge transfer is underappreciated and 
undervalued during such transfers.  This paper seeks to further understand the barriers to 
improve knowledge transfer for enabling successful technology transfer and knowledge 




a) Pharmaceutical Regulatory Context 
In 2008 The International Council for Harmonisation (ICH) published a guideline on 
Pharmaceutical Quality System Q10 [2], commonly referred to as “ICH Q10.”    The objectives of 
ICH Q10 are: 
a. to achieve product realization 
b. to establish and maintain a state of control 
c. to facilitate continual improvement.   
 
ICH Q10 positioned knowledge management (KM) as an enabler to the Pharmaceutical Quality 
System (PQS) (Figure 1) suggesting that effective knowledge management is required to realize 
an effective PQS, and therefore to achieve the objectives of ICH Q10.  This regulatory guidance 
marked the first time that knowledge management was identified as an expectation for the 
sector.  However, minimal guidance on what is required or how this might be achieved is provided 
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in ICH Q10.  Although the sector has struggled with KM adoption, no further regulatory guidance 
has been published beyond the Q&A document [3] since the release of ICH Q10.  However, the 
Q&A document also discusses what KM is not to be.  In particular, it is not viewed as an 
information technology (IT) system.  Rather, the ‘what’ and ‘how’ for KM were left up to 
individual organizations.  The absence of further guidance, such as models for best practices, 
guiding principles, or measures of progress or realization is a contributory factor as to why 
progress in KM has been slow and elusive in the sector.   
 
 
Figure 1 - ICH Q10 Pharmaceutical Quality System 
 
Formal research on knowledge management in the biopharmaceutical sector was undertaken by 
Kane in 2014 [1].  At that time, little guidance existed to describe how KM might actually enable 
a more effective pharmaceutical quality system.  Kane’s research has led to the establishment of 
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a model, known as the Pharma KM Blueprint [1] which consists of four key elements one of which 
is the premise of this paper: The Pharmaceutical Product Knowledge Lifecycle (PPKL) Model. The 
PPKL addresses the challenge of enabling knowledge flow in order to increase visibility, access 
and use of product and process knowledge assets across the product lifecycle.  Specifically, this 
model asserts the pharmaceutical product lifecycle diagram depicted in ICH Q10 [2]  does not 
account for the multiple instances of technology transfer that would typically occur over the 
lifecycle of a product, nor the generation and capture of tacit knowledge generated during 
technology transfer or continual improvement activities.  Kane’s model presented in Figure 2 
substitutes the ICHQ10 Technology Transfer lifecycle stage with an enhanced lifecycle stage 
entitled New Product Introduction and highlights the need for technology and knowledge 
transfer along the full lifecycle of the product. 
 
 
 Figure 2 - Pharmaceutical Product Knowledge Lifecycle (PPKL) highlighting technology and knowledge transfer in multiple points 
along the product lifecycle [1] 
 
While the PPKL model develops the concept of Technology and Knowledge Transfer (as 
highlighted in the orange bar in Figure 2), it is acknowledged that future research opportunities 
are warranted in the area of new product introduction and technology transfer. This paper 





Currently ICH Q12, Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle 
Management, Q12 [4], is in draft.  Q12 is intended to further advance the expectation that 
improved product and process knowledge can contribute to a reduction in the number post-
approval change submissions, as the accumulated knowledge gained during development and 
implementation of changes will manage risks to product quality.  These regulatory expectations 
should further increase the importance and urgency for the sector to be more effective at the 
practice of knowledge management.   
 
b) Technology Transfer’s Dependency on Knowledge Transfer 
A scan of current literature suggests the importance of successful technology transfer, and of 
knowledge to the success of technology transfer.  The PDA Technical Report No. 65 on 
Technology Transfer [5] states “technology transfer can affect drugs and patients”, clearly 
highlighting the importance of an effective technology transfer to ensure product outcomes 
and protect patients.  And Millili [6]  outlines examples where insufficient process knowledge 
result in a poorly scaled-up process, along with other undesirable outcomes including:  
• Non-robust processes (decreased process capability, i.e. Cpk) 
• Decreased reliability 
• Reduced production rates 
• Increased number of atypical events (e.g. defects, elegance issues, etc.) 
• Difficulty handling variations (raw materials, process controls, …) 
• Inefficient validation. 
 
Further examples in the literature refer to other areas where the sector struggles with 
transferring knowledge during technology transfer, such as contamination control and 
sterilization technology risks [7].  Consider the following issues and shortcomings cited on 
knowledge transfer effectiveness during technology transfer: 
 
• “…assays were transferred but the sending party did not provide complete information 
and some of the information was out-of-date…” [8] 
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• “…poor process understanding, coupled with incomplete documentation (i.e. 
codification) of all the required process parameters…” [9] 
 
• “The third mistake is not arranging for scientist-to-scientist interaction during the 
transfer process. Scientists from similar departments at both the transferring company 
and the receiving company need to get acquainted, understand the transfer process, 
and then work side by side at the bench or in the plant. Without that personal 
interaction, your transfer is risky” [10]  
 
• “…incomplete knowledge transfer…is a consistent problem…” [11] 
 
•  “…there was no master document to track all the information and it was sent out 
piecemeal to different points of contact…” [8] 
 
• “…providing incomplete information about the nature of the biopharmaceutical or 
protein molecule such as its properties, its activities, and its stability under different 
conditions. Often, companies know this information, but don’t pass it on…” [10] 
 
There is a clear opportunity to improve the effectiveness of knowledge transfer during 
technology transfer, which in turn will improve technology transfer outcomes and associated 
patient outcomes.  In better leveraging the knowledge of the organizations involved – and 
ensuring that knowledge is available and accessible, such improvements will also address, at 
least in part, the regulatory expectations emerging from ICH Q12. 
 
3) New Research to Advance Knowledge Transfer Understanding and 
Effectiveness 
Building on the foundational research by Kane, and the advancing expectation to better manage 
product and process knowledge highlighted in Q12 [4] and other business contexts [12], further 
research on knowledge management during at technology transfer has commenced by Lipa.  The 
research will explore elements of both explicit and tacit knowledge management during 
technology transfer.  Lipa’s preliminary research hypothesis is as follows: 
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a. The sector does not have a holistic end-to-end view of what it knows about its 
products across the product lifecycle, nor how to best ensure this knowledge 
‘flows’ to ensure the best possible product outcomes.  These outcomes include 
product realization through a readily available, cost effective and high-quality 
product to patients, as well as additional outcomes of operational efficiency and a 
workforce that has the knowledge it needs to do its best work. 
 
b. Further, tacit knowledge is critical but is not effectively managed or transferred 
during key activities in the product lifecycle, including key processes such as 
technology transfer. 
 
In order to raise awareness and to provide guidance on how to improve knowledge transfer 
associated with technology transfer, and to ultimately improve technology transfer outcomes, 
this research commences by characterizing the current state of how KM enables technology 
transfer, including perceived importance and effectiveness for explicit and tacit knowledge.   
The research approach is to gather input from multiple sources to establish a baseline on 
knowledge transfer effectiveness within technology transfer. 
 
Three distinct research activities were undertaken to gather input as follows: 
 
a. Literature review of industry guidance on technology transfer.   
b. Survey, from an audience survey conducted in April 2019, on the importance and 
effectiveness of knowledge transfer as part of technology transfer 
c. Expert interviews from international industry and health authorities  
 
Further additional research may include: 
a. Benchmark other industries on processes and proven effectiveness of knowledge 
transfer. 
b. Develop a model to describe the maturity of knowledge transfer. 
c. Develop recommendations for enhancing knowledge transfer during technology 






4) Results – Characterization of Current State Knowledge Transfer 
 
a) Literature Review:  Industry Guidance on Technology Transfer 
Initial research included a review of common industry guidance on technology transfer, to assess 
the extent to which knowledge transfer, knowledge management and tacit knowledge concepts 
are presented and explained, along with the extent of illustrative examples and guidance or tips 
on the ‘how’.  The following technology transfer guidance was reviewed, and the frequency of 
these concepts was tabulated and summarized in Table 1. 
• WHO Guidelines on Transfer of Technology in Pharmaceutical Manufacturing [13] 
• ISPE Good Practice:  Technology Transfer, 2nd Edition [14]  
• ISPE Good Practice:  Technology Transfer, 3rd Edition [15] 
• PDA Technical Report, No. 65, Technology Transfer [5] 
• PDA Tech Transfer Interest Group Report Out, PDA 2019 Annual Meeting (presentation) 
[16] 
A qualitative assessment was conducted on how well these guidance documents introduced the 
knowledge transfer concepts above, including how well they are collectively explained, whether 
they provided illustrative examples, and whether they provided guidance / tips on ‘how’.  These 
results are also provided along with author commentary in Table 1.   
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Table 1 - Summary of Guidance citing Knowledge Transfer as an Enabler to Technology Transfer 
 
 
On review of these guidance documents and the summary depicted in Table 1, the following 
are observations shared by Lipa.  In general:  
a. Technology Transfer guidance is often very ‘document-centric’ (i.e. focused on 
explicit knowledge) 
 
b. Knowledge management, mostly around explicit knowledge, is called out in 
guidance but is vague in what it means: 
o Little for supporting principles or guidance on how to do it effectively 
o Starting to change in places…but perhaps still not enough or fast enough. 
 
c. ‘Tacit’ knowledge is not often well recognized as a source of knowledge, nor is 
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Single reference, brief introduction to concepts.
ISPE
Good Practice Guide:  Technology 
Transfer (Second Edition, 
superseded )
2014 81 12 4 5 Limited Limited
Little to 
None
Solid references to the importance of KT and KM, 
and how successful TT is dependent.  Tacit concept 
introduced.
ISPE
Good Practice Guide:  Technology 
Transfer (Third Edition)
2018 152 21 13 14 Good Good Limited
KM cited as a driver for the update, strong 
guidance on the importance of underlying 
knowledge.  Solid examples for tacit knowledge.  
Some simple examples of how but examples are 
high level or conceptual only.
PDA
Technical Report No. 65, Technology 
Transfer






Brief introduction to concept of KM, but little 
beyond high level concepts linked to ICH Q10.
PDA
PDA Tech Transfer Interest Group 
Report Out, 2019 Annual Meeting 
(presentation)
2019 n/a yes yes no Limited Limited
Little to 
None
Included as this was a recent development and 
may lead to a revision to PDA TT Technical Report, 
and/or a Technical Report on KM.  KM focus 
appears exclusively document centric, no mention 
of tacit knowledge or related concepts.  
Inventories provided by type but concepts of KT / 
KM not well explained.
Terms:  TT = Technology Transfer;  KT = Knowledge Transfer;  KM = Knowledge Management
Frequency of 
Terms
How well these terms
are collectively…
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d. Technology Transfer risks of failure do not acknowledge concepts of insufficient 
knowledge transfer or availability. 
 
For ISPE guidance, the second edition of the Good Practice Guide was included as a baseline to 
compare against the third edition, to evaluate any changes over time.  The third edition [15] lists 
five areas of highlight for the revision, one of which is “Recognition that knowledge management 
is a critical component of effective technology transfer…”.  It is clear in the results summarized in 
Table 1 the presence of KM and related concepts has been significantly strengthened beyond a 
starting baseline from the second edition.   
 
For PDA guidance, the PDA Tech Transfer Interest Group at the 2019 PDA Annual Meeting in 
March 2019 in San Diego, California, shared the results of a recent survey on Technology 
Transfer [16].  Lipa attended the session where the PDA Tech Transfer survey results were 
shared.  The survey was intended to assess the current practices and future needs for 
improving the Technology Transfer process. The survey covered: 
• Demographics 
• Types of Technology Transfer Performed 
• The Technology Transfer Process 
• Use of Multi-Disciplinary Teams 
• Technology Transfer Tools 
• Challenges. 
 
The results indicated that KM would be an area where additional PDA guidance would be helpful.  
The subsequent discussion on KM in session focused heavily on a ‘master plan’ for knowledge 
management which primarily focused on documents and information.  Also, a set of KM “soft 
skills” was identified as required, although in the opinion of Lipa, these are primarily good 
business communication and team leadership skills, rather than traditional KM skills as described 
elsewhere [17].   
 
In general, across any of the guidance documents, there does not appear to be a measure for the 
effectiveness or completeness of knowledge transfer associated with technology transfer, with 
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the exception of document turnover lists. This will be further investigated during subsequent 
research.  
 
b) Survey: Audience Survey on Knowledge Transfer Enabling Successful 
Technology Transfer 
Once the literature review was complete and based on the review findings and the researcher’s 
own experiences, a survey was developed to further support the hypothesis problem statement 
by testing the opinion of a naïve audience.  The survey was designed to solicit their perspectives 
on the importance and effectiveness of knowledge transfer to enable an effective and efficient 
technology transfer.  This survey was deployed at a recent seminar, An Audience with 
Regulatory, Academia and Industry on The Role of Effective QRM & KM in Product Realization 
for Patients in the 21st Century on 04-April-2019 at Technological University Dublin.   
 
The survey was distributed to the audience of approximately 120 attendees, and 56 responses 
were received.  It is important to note results from this survey are considered directional in 
nature due to the qualitative nature of the questions provided, although useful comparisons 
can be made within the response data.  A detailed review of the complete survey results can be 
found in the monograph of the proceeding from the seminar [18].   
 
A key focus of the survey was to evaluate the perceived importance of both explicit and tacit 
knowledge to an effective and efficient technology transfer.   
Explicit knowledge was defined as: 
 Documents and other ‘codified’ knowledge that takes no explanation or dialog 
to fully understand.   
Tacit knowledge was defined as: 
Knowledge associated with experience, subject matter expertise, decision 
rationale, observation, undocumented history and other knowledge “in people’s 
heads.”   
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The survey also solicited opinions on the corresponding effectiveness for each explicit and tacit 
knowledge transfer.  The results are summarized in Figure 3. 
 
 
Figure 3 - Importance vs. Effectiveness for each Explicit and Tacit Knowledge Transfer 
 
The results indicate strong agreement that both explicit and tacit knowledge are critical to an 
effective and efficient technology transfer, with the relative criticality being generally similar 
(4.8 and 4.6 respectively on Figure 3).  When explicit knowledge transfer effectiveness is 
evaluated, the effectiveness of explicit knowledge transfer is only marginally effective (3.4).  
When tacit knowledge transfer effectiveness is evaluated, effectiveness of tacit knowledge 
transfer is somewhat ineffective (2.0).   
 
Although only directional in nature, these survey results support the importance of knowledge 
transfer to technology transfer outcomes.  Clearly, there is a gap between the reality of how 
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well we transfer (effectiveness) versus the importance of having the knowledge transferred.  
This gap exists for both explicit knowledge and tacit knowledge but is more prominent for tacit 
knowledge.  Advances to improve knowledge transfer effectiveness will benefit technology 
transfer outcomes, and ultimately benefit patients.   
 
c) Expert Interviews:  International Industry and Regulatory Authority experts 
Four experts were interviewed in Q2 2019 to explore their perspectives on the importance of 
knowledge transfer as a part of technology transfer, on the effectiveness of each explicit and 
tacit knowledge transfer, and expectations for tacit knowledge transfer.   The interview 
participants are blinded but represent the following perspectives, noting their input is their own 
opinion and does not represent the position of their affiliated organization: 
• Participant A:  Senior inspector & compliance manager, EU pharmaceutical regulatory 
authority.  Frequent international speaker, committee member and panelist with 18+ 
years’ experience. 
• Participant B:  Director, United States pharmaceutical regulatory authority.  Frequent 
international speaker, committee member and panelist with 25+ years’ experience.  
• Participant C:  Senior Director in Technology, United States, multinational 
biopharmaceutical company.  Experience of 25+ years’ in multiple roles and companies. 
• Participant D:  Senior Director, EU, multinational pharmaceutical company.  Experience 
of 30+ years’ in multiple roles and companies, including health authority and academic 
experience in the biopharmaceutical sector. 
The interviews followed a structured set of questions and were typically an hour long.  The 
interviews were transcribed, coded and responses summarized in Table 2.   
 
Table 2 - Summary of Expert Interviews 
Considering the end-to-end (E2E) product lifecycle depicted in ICH Q10 [2],  
To what extent do you agree that knowledge transfer could be improved for technology 
transfer, leading to better outcomes?    
Regulatory Authority Perspectives Industry Perspectives 
The ‘Big Picture’  The ‘Big Picture’ 
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• Lots of opportunity to improve 
• A number of companies do a good job 
• Initial technology transfer is critical 
• Starts with taking learning from 
development 
• Need honesty and transparency 
• Understand how much variability 
• Residual latent risk remains 
 
Business Process Challenges 
• Ceremonial writing of report 
• Many companies capture only part 
• Knowledge gets lost between development 
and commercial manufacturing 
• Deep investigations were eventually 
uncovered still in place at the old facility 
• Don’t lose in translation 
 
Document Challenges 
• Knowledge gets lost or buried in 
documents 
• Documents may not be in usable format 
• Documents may be long 
• Knowledge transfer is essential 
• Tech transfer as opportunity to give 
another group of people the ability and skill 
to do what you have been doing 
adequately 
• Could be improved deeper understanding 
and benefits would accrue, including cost, 
quality and availability 
• Technology transfer sometimes driven by a 
compliance need, not a knowledge need 
• Technology transfer sometimes seen as a 
tedious task that must be done 
 
Business Process Challenges 
• Many functions work in a vacuum 
• Not everyone knows what everyone else is 
doing 
• Delays due to needing to purchase or 
modify equipment not planned ahead 
• Ensure quality systems can handle new 
process 
• Approval delay for insufficient quality 
systems 
• Know how may not be transferred 
 
On a scale of 1 to 10 (10 = exceptional) 
How would you rate the range and average effectiveness of knowledge transfer of explicit 
knowledge during technology transfer?   
Regulatory Authority Perspectives Industry Perspectives 
Participant A:  
Average: 6 out of 10 
Range:  3 to 8 
 
Participant B:  
Average: 7 out of 10 
Range:  3 to 9 
Participant C:  
Average: 6 out of 10 
Range:  3 to 10 
 
Participant D:  
Average/ Range: “in the upper half, with wide 
standard deviation” 
 
On a scale of 1 to 10 (10 = exceptional) 
How would you rate the range and average effectiveness of knowledge transfer of tacit 
knowledge during technology transfer?   
Regulatory Authority Perspectives Industry Perspectives 
Participant A:  
Average: 3 out of 10 
Range:  1 to 5 
 
Participant B:  
Average: 5 out of 10 
Range:  1 to 7 
 
Participant C:  
Average: 7 out of 10 
Range:  n/a 
 
Participant D:  
Average / Range:  “Not as effective as explicit 




What expectations do you have for tacit knowledge transfer during technology transfer? 
Regulatory Authority Perspectives Industry Perspectives 
What to transfer 
• Expect much of this is tacit knowledge to 
do a task 
• How to run a process in a particular piece 
of equipment 
 
Expectations to capture & communicate 
• Understand impact of late discoveries or 
say you don’t know 
• Nothing expressly in marketing 
authorization requirements about tacit 
knowledge, but tacit knowledge really 
important to get transferred 
• Tacit knowledge should get looked at and 
written down 
• How risk is communicated to regulators is a 
problem 
• Tension created without transparent 
sharing of scientific information 
 
What to transfer 
• Summarize key development activities 
• Capture pilot scale knowledge 
• Capture instabilities 
• Capture failures 
• Learn from failures 
 
Consider this statement:   
“We can do the knowledge transfer associated with a technology transfer via Fed Ex.” 
Do you agree or disagree?  Why? 




• People need to talk to each other 
• People need to spend time with each other 
working through a process 
• False! 
• Fundamentally and profoundly disagree 
 
Human Element 
• There is a human element 
• Need to talk 
• Need to walk through process 
• Need to get experience at sending site 
 
Sources of Variability 
• Levels of experience & understanding 
• Language translation challenges 
• Variability due to shift work 
 
 
These results speak well for themselves; a summary is as follows:  
1. Knowledge transfer can be improved and would have meaningful positive impact to 
technology transfer outcomes, including cost, quality and product availability.   
2. Some companies appear to do well but this is the exception, not the norm. 
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3. Transparency on the level of process understanding is critical to a productive regulatory 
dialog. 
4. Often knowledge gets ‘stuck’, often based on process or people barriers (e.g. judgement 
it is not important, buried in long documents, may be in an unusable format. 
5. On average, knowledge transfer effectiveness of explicit knowledge is marginal and 
there is wide variation. 
6. On average, knowledge transfer effectiveness of tacit knowledge is ineffective to 
marginal and there is wide variation. 
7. Successful technology transfer required human to human interactions, preferably face 
to face and time to walk through the details of a process to explore details, sensitivities, 
what is not known, etc. 
8. There is a clear desire that we must get better at this as a sector. 
 
5) Summative Discussion 
The three independent research activities and resulting data correlate well and suggest these key 
findings: 
1. Overall, knowledge transfer is critical to a successful and sustainable technology transfer.  
Ineffective knowledge transfer can have a long-lasting impact on the ability of the 
receiving site to provide cost-effective, high-quality product with the desired availability.   
2. Knowledge to be transferred associated with technology transfer is biased toward explicit 
knowledge (e.g. documents).  This explicit knowledge is critical to the success of the 
transfer yet we as a sector are only marginally effective at it – it is clearly not a strength.  
There is some supporting guidance on explicit knowledge that should be transferred, but 
not prescriptive means on how to do this or how to measure effectiveness.   
3. Tacit knowledge associated with technology transfer is not widely recognized as an asset 
to be transferred, nor is there evidence to suggest we as a sector do it effectively.  There 
is limited understanding on what tacit knowledge is, why it is important and how it can 
be transferred, including how to measure effectiveness of transfer.  There is little 
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acknowledgement of tacit knowledge in common industry guidance for technology 
transfer, although there has been an upward trend very recently on calling out tacit 
knowledge categorically.     
4. Regulatory authorities and industry are generally well aligned on these issues and their 
impact.  Both recognize the opportunity – and the need – to improve for the good of 
patients. 
 
These findings support the problem statements which are being explored, namely, that 
knowledge does not ‘flow’ readily through technology transfer, and that tacit knowledge is 
critical but is not effectively managed or transferred.  The subsequent research activities to 
benchmark other industries, develop a knowledge transfer maturity model and associated 
recommendations to improve knowledge transfer will proceed with the aim to address this 
opportunity.   
 
6) Conclusion 
In conclusion, knowledge management is still a relatively immature practice in the 
biopharmaceutical sector, especially when compared to Quality Risk Management, Change 
Management and other practice domains.  The need for improved knowledge transfer for 
technology transfer, as a key focus point of knowledge management in the biopharmaceutical 
sector, is evident given the findings presented in this paper, supported by the broad alignment 
and recognition of the issue across different cohorts presented herein.  This KM focus first and 
foremost to protect the patient through availability of a high quality, cost effective product, and 
present the opportunity pursue other business drivers which ensure the continued 
competitiveness of the organizations in the sector [12].   
 
The next phases of research by Lipa as introduced in this paper intend to provide practical advice 
to help the sector apply good KM practices to improve technology transfer outcomes through 
the following: 
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a. Benchmark other industries on processes and proven effectiveness of knowledge 
transfer. 
b. Develop a model to describe the maturity of knowledge transfer. 
c. Develop recommendations for enhancing knowledge transfer during technology 
transfer, including any supporting tools, assessments or models to accelerate post-
research uptake. 
 
The initial findings presented within this paper well justify the planned efforts in this area. 
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